The combination of bevacizumab (Avastin) and erlotinib (Tarceva) is superior to erlotinib alone as upfront treatment for non–small cell lung cancer (NSCLC) harboring EGFR
mutations. A preplanned interim analysis of the phase III study known as NEJ026 showed a median progression-free survival (PFS) by independent review (the primary endpoint) of 16.9 months with the bevacizumab/erlotinib combination compared with 13.3 months with erlotinib by itself,1
said Naoki Furuya, MD, PhD, at the 2018 ASCO Annual Meeting.
The difference represents a 39.5% relative advantage on the primary endpoint favoring the combination (HR, 0.605; 95% CI, 0.417-0.877; P
“The bevacizumab/erlotinib combination is considered a new standard therapy in patients with untreated EGFR
-mutated NSCLC,” he said.
... to read the full story